SE9101642D0
(sv)
*
|
1991-05-30 |
1991-05-30 |
Kabi Pharmacia Ab |
Phospholipids
|
DK198991D0
(da)
*
|
1991-12-10 |
1991-12-10 |
Simanol A S |
Fiskeprodukt
|
SE9200541D0
(sv)
*
|
1992-02-24 |
1992-02-24 |
Kabi Pharmacia Ab |
New usee of omega-3-fatty acids
|
CA2159823C
(en)
*
|
1993-04-29 |
2004-08-31 |
Michel Perrut |
Processes for chromatographic fractionation of fatty acids and their derivatives
|
US20050027004A1
(en)
*
|
1993-06-09 |
2005-02-03 |
Martek Biosciences Corporation |
Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
|
US5767156A
(en)
*
|
1993-10-06 |
1998-06-16 |
Peptide Technology Limited |
Polyunsaturated fatty acids and uses thereof
|
IT1264987B1
(it)
*
|
1993-12-14 |
1996-10-17 |
Prospa Bv |
Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
|
GB9404483D0
(en)
*
|
1994-03-08 |
1994-04-20 |
Norsk Hydro As |
Refining marine oil compositions
|
IT1274734B
(it)
*
|
1994-08-25 |
1997-07-24 |
Prospa Bv |
Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
|
IL122405A
(en)
*
|
1995-06-07 |
2003-04-10 |
Martek Biosciences Corp |
Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
|
CA2236089C
(en)
*
|
1995-11-24 |
2002-03-05 |
Loders-Croklaan B.V. |
Composition based on fish oil
|
US5866150A
(en)
*
|
1996-03-20 |
1999-02-02 |
Aquaculture Technology Incorporated |
Antibacterially active extracts from the marine algae chaetoceros and methods of use
|
WO1998057628A1
(fr)
*
|
1997-06-16 |
1998-12-23 |
Nippon Suisan Kaisha, Ltd. |
Composition capable de supprimer le facteur de risque pendant l'exercice
|
US20020037876A1
(en)
*
|
1998-06-25 |
2002-03-28 |
Yissum Research Development Company Of Hebrew University Of Jerusalem |
Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
|
IL121165A0
(en)
*
|
1997-06-26 |
1997-11-20 |
Yissum Res Dev Co |
Pharmaceutical compositions containing carboxylic acids and derivatives thereof
|
JP2001520304A
(ja)
*
|
1997-10-23 |
2001-10-30 |
ザ、プロクター、エンド、ギャンブル、カンパニー |
脂肪酸、石鹸、界面活性剤系、およびそれらをベースにした消費製品
|
NO309795B1
(no)
*
|
1998-07-01 |
2001-04-02 |
Norsk Hydro As |
FremgangsmOte for O stabilisere oljer samt anvendelse derav, fremgangsmOte for O stabilisere pigmenter, og fremgangsmOte for fremstilling av for
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
IT1308613B1
(it)
*
|
1999-02-17 |
2002-01-09 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
|
US7112609B2
(en)
*
|
1999-06-01 |
2006-09-26 |
Drugtech Corporation |
Nutritional supplements
|
US6998501B1
(en)
|
1999-08-30 |
2006-02-14 |
Ocean Nutrition Canada Limited |
Nutritional supplement for lowering serum triglyceride and cholesterol levels
|
US6346231B1
(en)
|
1999-10-06 |
2002-02-12 |
Joar Opheim |
Flavored gelatin capsule and method of manufacture
|
US6395778B1
(en)
|
2000-01-11 |
2002-05-28 |
Omegatech, Inc. |
Process for making an enriched mixture of polyunsaturated fatty acid esters
|
ES2298197T3
(es)
*
|
2000-01-31 |
2008-05-16 |
Harting S.A. |
Composiciones que contienen esteres de acidos grasos de fitosterol y de policosanol para reducir el colesterol y los trigliceridos de la sangre.
|
US6890894B2
(en)
*
|
2000-02-22 |
2005-05-10 |
The Procter & Gamble Company |
Fatty acids, soaps surfactant systems, and consumer products based thereon
|
CA2304906A1
(en)
*
|
2000-04-07 |
2001-10-07 |
1411198 Ontario Limited |
13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
|
EP1157692B1
(en)
*
|
2000-05-22 |
2005-10-05 |
Pro Aparts - Investimentos E Consultoria Lda |
Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
|
US6667064B2
(en)
|
2000-08-30 |
2003-12-23 |
Pilot Therapeutics, Inc. |
Composition and method for treatment of hypertriglyceridemia
|
ITMI20010129A1
(it)
|
2001-01-25 |
2002-07-25 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
|
ITMI20012384A1
(it)
*
|
2001-11-12 |
2003-05-12 |
Quatex Nv |
Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
|
US8729124B2
(en)
*
|
2002-03-05 |
2014-05-20 |
Pronova Biopharma Norge As |
Use of EPA and DHA in secondary prevention
|
NZ518504A
(en)
*
|
2002-04-22 |
2005-05-27 |
Ind Res Ltd |
Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions
|
RU2331415C2
(ru)
*
|
2002-06-17 |
2008-08-20 |
Медести Ресерч Энд Продакшн С.Р.Л. |
Длинноцепочечные ненасыщенные оксигенированные соединения и их применение в области терапии, косметики и питания
|
SE0202188D0
(sv)
|
2002-07-11 |
2002-07-11 |
Pronova Biocare As |
A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
|
EP2295529B2
(en)
|
2002-07-11 |
2022-05-18 |
Basf As |
Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
|
US7279018B2
(en)
|
2002-09-06 |
2007-10-09 |
Fortum Oyj |
Fuel composition for a diesel engine
|
US7041840B2
(en)
*
|
2002-12-18 |
2006-05-09 |
Alberta Research Council Inc. |
Antioxidant triacylglycerols and lipid compositions
|
DE10261067A1
(de)
*
|
2002-12-24 |
2004-08-05 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
|
DE10261061A1
(de)
*
|
2002-12-24 |
2004-07-15 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
|
US20040235948A1
(en)
*
|
2003-03-05 |
2004-11-25 |
Solvay Pharmaceuticals Gmbh |
Treatment of diabetic patients with omega-3-fatty acids
|
DE10317109A1
(de)
*
|
2003-04-14 |
2004-11-11 |
Cognis Deutschland Gmbh & Co. Kg |
Zubereitungen zur oralen Aufnahme
|
US7759507B2
(en)
|
2003-09-05 |
2010-07-20 |
Abbott Laboratories |
Lipid system and methods of use
|
US8052992B2
(en)
*
|
2003-10-22 |
2011-11-08 |
Enzymotec Ltd. |
Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
|
SE0303513D0
(sv)
*
|
2003-12-19 |
2003-12-19 |
Pronova Biocare As |
Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
|
ITMI20040069A1
(it)
|
2004-01-21 |
2004-04-21 |
Tiberio Bruzzese |
Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
|
GB0403247D0
(en)
|
2004-02-13 |
2004-03-17 |
Tillotts Pharma Ag |
A pharmaceutical composition
|
US7022713B2
(en)
*
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
EP1600060A1
(en)
|
2004-05-25 |
2005-11-30 |
Cognis IP Management GmbH |
Oral and/or topical compositions comprising prebiotics and fatty acid
|
US20060020031A1
(en)
*
|
2004-07-26 |
2006-01-26 |
Roger Berlin |
Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
|
WO2006017692A2
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
US9000040B2
(en)
|
2004-09-28 |
2015-04-07 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US9012506B2
(en)
|
2004-09-28 |
2015-04-21 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
EP1656935A1
(en)
*
|
2004-11-12 |
2006-05-17 |
Cognis IP Management GmbH |
Use of physiologically active fatty acids for the treatment of pruritus
|
EP1656934A1
(en)
*
|
2004-11-12 |
2006-05-17 |
Cognis IP Management GmbH |
Use of physiologically active fatty acids for treating lipodystrophy
|
BRPI0518398A2
(pt)
*
|
2004-12-06 |
2008-11-18 |
Reliant Pharmaceuticals Inc |
Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos
|
CN101098690A
(zh)
*
|
2004-12-06 |
2008-01-02 |
瑞莱恩特医药品有限公司 |
用于血脂治疗的ω-3脂肪酸和脂血异常剂
|
US20060135610A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Bortz Jonathan D |
Cardiovascular compositions
|
CA2600429A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Reliant Pharmaceuticals, Inc. |
Treatment with statin and omega-3 fatty acids and a combination product thereof
|
WO2006117664A1
(en)
|
2005-05-04 |
2006-11-09 |
Pronova Biopharma Norge As |
New dha derivatives and their use as medicaments
|
CN101213281B
(zh)
*
|
2005-05-04 |
2013-03-13 |
普罗诺瓦生物医药挪威公司 |
新的dha衍生物及其作为药物的用途
|
WO2006123550A1
(ja)
*
|
2005-05-16 |
2006-11-23 |
Nippon Suisan Kaisha, Ltd. |
炎症性疾患予防又は治療剤
|
US20060292217A1
(en)
*
|
2005-06-03 |
2006-12-28 |
Schmidt Robbin D |
Nutritional supplement and soft gelatin capsule delivery system
|
CN101252837A
(zh)
*
|
2005-07-28 |
2008-08-27 |
瑞莱恩特医药品有限公司 |
用二氢吡啶类钙通道阻断剂和Omega-3脂肪酸及其组合产品的治疗
|
ITMI20051560A1
(it)
*
|
2005-08-10 |
2007-02-11 |
Tiberio Bruzzese |
Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
|
DE102005040463A1
(de)
|
2005-08-26 |
2007-03-01 |
Cognis Ip Management Gmbh |
Verwendung von Gemischen aus Polyphenolen und physiologisch aktiven ungesättigten Fettstoffen
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
US20070104779A1
(en)
*
|
2005-11-07 |
2007-05-10 |
Rongen Roelof M |
Treatment with omega-3 fatty acids and products thereof
|
DE102005054577A1
(de)
|
2005-11-16 |
2007-05-24 |
Cognis Ip Management Gmbh |
Verwendung von Estern ungesättigter, physiologisch aktiver Fettsäuren als Nährmedien für Zellkulturen
|
CA2625640A1
(en)
*
|
2005-12-09 |
2007-06-21 |
Drugtech Corporation |
Intravenous essential fatty acid emulsion
|
WO2007075841A1
(en)
*
|
2005-12-20 |
2007-07-05 |
Cenestra, Llc |
Omega 3 fatty acid formulations
|
US20070265340A1
(en)
*
|
2006-01-05 |
2007-11-15 |
Shalwitz Robert A |
Treatment of fatty liver
|
WO2007103186A2
(en)
|
2006-03-03 |
2007-09-13 |
Fmc Corporation |
Method and apparatus for the preparation of capsules
|
US8784886B2
(en)
*
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
EP2081550B2
(en)
|
2006-03-09 |
2021-05-26 |
Reliant Pharmaceuticals, Inc. |
Coating capsules with active pharmaceutical ingredients
|
JP5591469B2
(ja)
|
2006-05-31 |
2014-09-17 |
持田製薬株式会社 |
多重リスク患者の心血管イベント発症予防用組成物
|
JP2009544701A
(ja)
*
|
2006-07-21 |
2009-12-17 |
リライアント・ファーマシューティカルズ・インコーポレイテッド |
オメガ3脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
|
EP2083622A4
(en)
*
|
2006-10-18 |
2009-12-09 |
Reliant Pharmaceuticals Inc |
METHODS OF USING OMEGA-3 FATTY ACIDS TO REDUCE LP-PLA2 RATES
|
MX2009004337A
(es)
*
|
2006-11-01 |
2009-05-22 |
Pronova Biopharma Norge As |
Compuestos lipidos omega-3.
|
KR101438177B1
(ko)
*
|
2006-11-01 |
2014-09-05 |
프로노바 바이오파마 너지 에이에스 |
페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
|
BRPI0717972A2
(pt)
*
|
2006-11-01 |
2013-11-12 |
Pronova Biopharma Norge As |
Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar)
|
RU2509071C2
(ru)
*
|
2006-11-01 |
2014-03-10 |
Пронова Биофарма Норге Ас |
Новые липидные соединения
|
US20080306154A1
(en)
*
|
2006-11-03 |
2008-12-11 |
My Svensson |
Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
|
US20080125490A1
(en)
*
|
2006-11-03 |
2008-05-29 |
My Svensson |
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
|
BRPI0718393A2
(pt)
*
|
2006-11-03 |
2013-11-26 |
Pronova Biopharma Norge As |
Álcoois de ácido graxo
|
US20100130611A1
(en)
*
|
2006-12-20 |
2010-05-27 |
Cenestra Llc |
Omega 3 fatty acid formulations
|
EP1967197A1
(en)
*
|
2007-03-09 |
2008-09-10 |
Cognis IP Management GmbH |
Use of preparations, purifications and extracts of aloe
|
WO2009052182A1
(en)
|
2007-10-15 |
2009-04-23 |
Jbs United, Inc. |
Method for increasing performance of offspring
|
CN101801416B
(zh)
|
2007-06-29 |
2012-10-24 |
武田药品工业株式会社 |
无缝胶囊
|
EP2173699A4
(en)
*
|
2007-06-29 |
2014-04-16 |
Dsm Ip Assets Bv |
PRODUCTION AND PURIFICATION OF POLYUNSATURATED FATTY ACID ESTERS
|
US20090011012A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Baum Seth J |
Fatty acid compositions and methods of use
|
WO2009056983A1
(en)
*
|
2007-10-31 |
2009-05-07 |
Pronova Biopharma Norge As |
New dha derivatives and their use as medicaments
|
EP2211881A4
(en)
*
|
2007-11-01 |
2012-01-04 |
Wake Forest University School Of Medicine |
COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS
|
US8343753B2
(en)
*
|
2007-11-01 |
2013-01-01 |
Wake Forest University School Of Medicine |
Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
|
WO2009070589A1
(en)
*
|
2007-11-30 |
2009-06-04 |
Jbs United, Inc. |
Method and composition for treating pulmonary hemorrhage
|
US8575409B2
(en)
|
2007-12-20 |
2013-11-05 |
Syntroleum Corporation |
Method for the removal of phosphorus
|
CA2711814A1
(en)
*
|
2008-01-10 |
2009-07-16 |
Takeda Pharmaceutical Company Limited |
Capsule formulation
|
US20090182049A1
(en)
*
|
2008-01-16 |
2009-07-16 |
Joar Arild Opheim |
Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
|
WO2009139641A1
(en)
|
2008-05-15 |
2009-11-19 |
Pronova Biopharma Norge As |
Krill oil process
|
US20090300971A1
(en)
|
2008-06-04 |
2009-12-10 |
Ramin Abhari |
Biorenewable naphtha
|
US8581013B2
(en)
|
2008-06-04 |
2013-11-12 |
Syntroleum Corporation |
Biorenewable naphtha composition and methods of making same
|
KR20110058775A
(ko)
|
2008-08-07 |
2011-06-01 |
에스피에이쏘씨에따프로도티안티비오티씨에스피.에이 |
증후성 심부전의 장기 치료
|
ES2632967T3
(es)
|
2008-09-02 |
2017-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
|
US20100062057A1
(en)
*
|
2008-09-10 |
2010-03-11 |
Pronova BioPharma Norge AS. |
Formulation
|
WO2010040012A1
(en)
*
|
2008-10-01 |
2010-04-08 |
Martek Biosciences Corporation |
Compositions and methods for reducing triglyceride levels
|
US8231804B2
(en)
|
2008-12-10 |
2012-07-31 |
Syntroleum Corporation |
Even carbon number paraffin composition and method of manufacturing same
|
US8563792B2
(en)
*
|
2008-12-16 |
2013-10-22 |
Cetane Energy, Llc |
Systems and methods of generating renewable diesel
|
DK2384192T3
(en)
|
2009-01-05 |
2018-01-08 |
Calanus As |
BIOLOGICAL OIL COMPOSITION, FORMULATIONS CONTAINING THE OIL COMPOSITION, AND ITS USE TO PREVENT OR TREAT CARDIOVASCULAR DISEASE
|
CA2751576C
(en)
|
2009-02-10 |
2018-07-03 |
Amarin Pharma, Inc. |
Use of eicosapentaenoic acid to treat hypertriglyceridemia
|
US11395811B2
(en)
|
2009-03-09 |
2022-07-26 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture comprising EPA and DHA in free acid form and a surfactant, and methods and uses thereof
|
US9034389B2
(en)
|
2009-03-11 |
2015-05-19 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
US8241672B2
(en)
*
|
2009-03-11 |
2012-08-14 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
US20110071090A1
(en)
*
|
2009-03-11 |
2011-03-24 |
Stable Solutions Llc |
Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
|
US8993625B2
(en)
|
2009-03-11 |
2015-03-31 |
Stable Solutions Llc |
Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
|
US9062275B2
(en)
*
|
2009-04-17 |
2015-06-23 |
Natac Pharma, S.L. |
Compositions rich in omega-3 fatty acids with a low content in phytanic acid
|
NO2424356T3
(sv)
|
2009-04-29 |
2018-01-20 |
|
|
NZ595789A
(en)
|
2009-04-29 |
2014-05-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
RU2519043C2
(ru)
|
2009-06-15 |
2014-06-10 |
Амарин Фарма, Инк. |
Композиции и способы понижения уровня триглицеридов без повышения уровня хс-лпнп у субъекта, получающего сопутствующую терапию
|
US9101942B2
(en)
|
2009-06-16 |
2015-08-11 |
Aurora Algae, Inc. |
Clarification of suspensions
|
US20110033595A1
(en)
*
|
2009-08-10 |
2011-02-10 |
Rudolf Krumbholz |
Fatty acid fractionation process, fatty acid products and use thereof
|
US20110033531A1
(en)
*
|
2009-08-10 |
2011-02-10 |
Dracopharma, Inc. |
Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
|
US20110038910A1
(en)
|
2009-08-11 |
2011-02-17 |
Atrium Medical Corporation |
Anti-infective antimicrobial-containing biomaterials
|
ES2716984T3
(es)
*
|
2009-09-10 |
2019-06-18 |
Dupont Nutrition Usa Inc |
Cápsulas de alginato sin costuras
|
US20110071176A1
(en)
|
2009-09-23 |
2011-03-24 |
Amarin Pharma, Inc. |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
WO2011041710A2
(en)
*
|
2009-10-01 |
2011-04-07 |
Martek Biosciences Corporation |
Docosahexaenoic acid gel caps
|
US9717703B2
(en)
|
2009-10-16 |
2017-08-01 |
Glaxosmithkline Llc |
Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
|
CN102724972A
(zh)
*
|
2009-10-23 |
2012-10-10 |
普罗诺瓦生物医药挪威公司 |
脂肪酸油混合物的包衣胶囊和包衣片剂
|
ES2862980T3
(es)
*
|
2009-12-30 |
2021-10-08 |
Basf Pharma Callanish Ltd |
Composiciones de ácido graso poliinsaturado obtenibles mediante un proceso de separación cromatográfica en lecho móvil simulado
|
AU2013204090B2
(en)
*
|
2009-12-30 |
2015-01-29 |
Basf Pharma (Callanish) Limited |
Simulated moving bed chromatographic separation process
|
US20110178105A1
(en)
*
|
2010-01-15 |
2011-07-21 |
E.I. Du Pont De Nemours And Company |
Clinical benefits of eicosapentaenoic acid in humans
|
CA3066588C
(en)
*
|
2010-03-04 |
2022-03-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US8394900B2
(en)
|
2010-03-18 |
2013-03-12 |
Syntroleum Corporation |
Profitable method for carbon capture and storage
|
BR112012027915A2
(pt)
|
2010-05-13 |
2018-10-23 |
Nitromega Corp |
nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
|
ITMI20100961A1
(it)
*
|
2010-05-27 |
2011-11-28 |
Erredue Spa |
Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione
|
US10322213B2
(en)
*
|
2010-07-16 |
2019-06-18 |
Atrium Medical Corporation |
Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
|
US20140004186A1
(en)
*
|
2010-09-08 |
2014-01-02 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
|
US20140017308A1
(en)
*
|
2010-09-08 |
2014-01-16 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
|
AR082930A1
(es)
*
|
2010-09-08 |
2013-01-16 |
Pronova Biopharma Norge As |
Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
|
NZ757815A
(en)
|
2010-11-29 |
2020-05-29 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
CL2010001587A1
(es)
|
2010-12-27 |
2013-01-11 |
Golden Omega S A |
Proceso de preparacion de un concentrado de etil esteres de acidos grasos omega-3 que comprende sobre el 80% en peso de dichos esteres en configuracion cis y sus dobles enlaces separados por una unidad metilenica.
|
US9119826B2
(en)
|
2011-02-16 |
2015-09-01 |
Pivotal Therapeutics, Inc. |
Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
|
US8715648B2
(en)
|
2011-02-16 |
2014-05-06 |
Pivotal Therapeutics Inc. |
Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
|
US8952000B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
|
US8951514B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
|
EP2540292A1
(en)
*
|
2011-06-28 |
2013-01-02 |
Nestec S.A. |
DHA and EPA in the reduction of oxidative stress
|
US8865685B2
(en)
|
2011-06-30 |
2014-10-21 |
Johnson & Johnson Vision Care, Inc. |
Esters for treatment of ocular inflammatory conditions
|
GB201111601D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
New process
|
GB201111591D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
Further new process
|
GB201111595D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
Improved process
|
GB201111589D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
New modified process
|
GB201111594D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
New improved process
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
EP2775837A4
(en)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF TREATING HYPERTRIGLYCERIDEMIA
|
CA2855246A1
(en)
|
2011-11-09 |
2013-05-16 |
Andrew Boam |
Membrane-based processes for reducing at least one impurity and making a concentrate comprising at least one natural component from a non-marine fatty acid oil mixture, and compositions resulting thereof
|
KR101466617B1
(ko)
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
WO2013072767A1
(en)
|
2011-11-18 |
2013-05-23 |
Pronova Biopharma Norge As |
Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
|
ES2891473T3
(es)
|
2012-01-06 |
2022-01-28 |
Amarin Pharmaceuticals Ie Ltd |
Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
|
HUE039659T2
(hu)
|
2012-01-06 |
2019-01-28 |
Omthera Pharmaceuticals Inc |
Szabad sav formájában lévõ Omega-3 többszörösen telítetlen zsírsavak DPA-dúsított készítményei
|
AU2013201793B2
(en)
*
|
2012-01-06 |
2015-03-19 |
Chrysalis Pharma Ag |
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
|
WO2013130411A1
(en)
*
|
2012-02-27 |
2013-09-06 |
Essentialis, Inc. |
Salts of potassium atp channel openers and uses thereof
|
US20160228397A1
(en)
|
2012-03-30 |
2016-08-11 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions
|
US9480651B2
(en)
|
2012-03-30 |
2016-11-01 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
|
US10898458B2
(en)
|
2012-03-30 |
2021-01-26 |
Micelle Biopharma, Inc. |
Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
|
CA2867168A1
(en)
|
2012-03-30 |
2013-10-03 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions
|
US8652518B2
(en)
|
2012-04-15 |
2014-02-18 |
Jahahreeh Finley |
Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
|
NO2659881T3
(sv)
|
2012-04-30 |
2018-04-28 |
|
|
CN104661654A
(zh)
*
|
2012-05-07 |
2015-05-27 |
翁特拉制药公司 |
他汀类药物和ω-3脂肪酸的组合物
|
CN113025434A
(zh)
*
|
2012-05-14 |
2021-06-25 |
日本水产株式会社 |
高度不饱和脂肪酸或高度不饱和脂肪酸乙酯及其制造方法、药品、添加剂或食品
|
WO2013192109A1
(en)
|
2012-06-17 |
2013-12-27 |
Matinas Biopharma, Inc. |
Omega-3 pentaenoic acid compositions and methods of use
|
SG10201913646PA
(en)
|
2012-06-29 |
2020-03-30 |
Amarin Pharmaceuticals Ie Ltd |
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
|
WO2014060847A1
(en)
|
2012-09-24 |
2014-04-24 |
Aker Biopharma As |
Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
|
US10105376B2
(en)
|
2012-09-24 |
2018-10-23 |
Aker Biomarine Antarctic As |
Omega-3 compositions
|
JP2016500055A
(ja)
*
|
2012-10-23 |
2016-01-07 |
ディーキン・ユニバーシティー |
トリグリセリドを低減させる方法
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
EP2928462A4
(en)
*
|
2012-12-06 |
2016-06-01 |
Matinas Biopharma Inc |
METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
|
US10123986B2
(en)
|
2012-12-24 |
2018-11-13 |
Qualitas Health, Ltd. |
Eicosapentaenoic acid (EPA) formulations
|
US9629820B2
(en)
|
2012-12-24 |
2017-04-25 |
Qualitas Health, Ltd. |
Eicosapentaenoic acid (EPA) formulations
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
GB201300354D0
(en)
|
2013-01-09 |
2013-02-20 |
Basf Pharma Callanish Ltd |
Multi-step separation process
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
WO2014134053A1
(en)
*
|
2013-02-26 |
2014-09-04 |
Jiva Pharma, Inc. |
Ascorbate esters of omega-3 fatty acids
|
US9328303B2
(en)
|
2013-03-13 |
2016-05-03 |
Reg Synthetic Fuels, Llc |
Reducing pressure drop buildup in bio-oil hydroprocessing reactors
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US9266973B2
(en)
|
2013-03-15 |
2016-02-23 |
Aurora Algae, Inc. |
Systems and methods for utilizing and recovering chitosan to process biological material
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US20140274922A1
(en)
|
2013-03-15 |
2014-09-18 |
Aurora Algae, Inc. |
Algal omega 7 compositions
|
US8969259B2
(en)
|
2013-04-05 |
2015-03-03 |
Reg Synthetic Fuels, Llc |
Bio-based synthetic fluids
|
US8802880B1
(en)
|
2013-05-07 |
2014-08-12 |
Group Novasep |
Chromatographic process for the production of highly purified polyunsaturated fatty acids
|
US9428711B2
(en)
|
2013-05-07 |
2016-08-30 |
Groupe Novasep |
Chromatographic process for the production of highly purified polyunsaturated fatty acids
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
WO2015011724A2
(en)
|
2013-07-22 |
2015-01-29 |
Kms Health Center Pvt Ltd |
A novel omega -3 fatty acid composition with a plant extract
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
KR102174942B1
(ko)
|
2013-10-29 |
2020-11-06 |
틸로츠 파마 아게 |
지연 방출 약물 제형
|
ES2826201T3
(es)
|
2013-10-30 |
2021-05-17 |
Patheon Softgels Inc |
Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados
|
US20150133554A1
(en)
*
|
2013-11-08 |
2015-05-14 |
Omega Protein Corporation |
Purification of dpa enriched oil
|
EP3118186B1
(fr)
|
2013-12-11 |
2022-02-09 |
Novasep Process |
Installation chromatographique de production d acides gras polyinsatures
|
KR102165406B1
(ko)
|
2014-01-07 |
2020-10-14 |
노바셉 프로세스 |
방향족 아미노산의 정제 방법
|
CA2950344C
(en)
|
2014-06-06 |
2023-09-19 |
Marine Ingredients, Llc |
Omega-3 compositions, dosage forms, and methods of use
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
US9895333B2
(en)
|
2014-06-26 |
2018-02-20 |
Patheon Softgels Inc. |
Enhanced bioavailability of polyunsaturated fatty acids
|
TWI532482B
(zh)
*
|
2014-09-01 |
2016-05-11 |
國立中山大學 |
阿魏酸用以製備提升血紅蛋白釋放氧氣至人體內各器官及周邊組織能力之藥物的用途
|
EP3273954B1
(en)
|
2015-03-26 |
2020-10-28 |
Tiberio Bruzzese |
Purified compositions of polyunsaturated fatty acids, their preparation method and their use
|
EP3340982B1
(en)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
EP3219209A1
(de)
|
2016-03-19 |
2017-09-20 |
DMK Deutsches Milchkontor GmbH |
Lagerstabile milchzubereitung enthaltend ascorbinsäure
|
CA3029262A1
(en)
|
2016-06-27 |
2018-01-04 |
Achillion Pharmaceuticals, Inc. |
Quinazoline and indole compounds to treat medical disorders
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
IT201700054543A1
(it)
|
2017-05-19 |
2018-11-19 |
Gleaner Srls |
Preparato come fonte di Omega-3
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
WO2019241563A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for lowering triglyceride levels with a concentrated fish oil-based pharmaceutical composition
|
EP3586640A1
(en)
|
2018-06-21 |
2020-01-01 |
Nuseed Pty Ltd |
Dha enriched polyunsaturated fatty acid compositions
|
EP3841086A4
(en)
|
2018-08-20 |
2022-07-27 |
Achillion Pharmaceuticals, Inc. |
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
|
MA50490A
(fr)
|
2018-09-24 |
2020-09-02 |
Amarin Pharmaceuticals Ie Ltd |
Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
|